Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nephrol Dial Transplant ; 18(12): 2596-600, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14605283

ABSTRACT

BACKGROUND: Hyperhomocysteinaemia is a putative risk factor for atherothrombotic cardiovascular disease in the haemodialysis population. High-dose vitamin B therapy does not entirely normalize elevated plasma total homocysteine (tHcy) levels in haemodialysis patients. Alternative therapies to reduce tHcy further are therefore required. Modifications of the dialysis regimen may result in a better removal of Hcy. We examined the effect of dialyser membrane pore size on tHcy levels in vitamin-replete chronic haemodialysis patients. METHODS: Forty-five haemodialysis patients were dialysed during 4 weeks with a low-flux, a high-flux and a super-flux membrane, in random order. Pre-dialysis tHcy was determined at baseline and every 4 weeks. In 18 patients, plasma tHcy before and after dialysis and dialysate tHcy concentrations were measured. RESULTS: Pre-dialysis tHcy decreased significantly during 4 weeks super-flux dialysis (-14.6 +/- 2.8%), whereas it remained stable during high-flux (+0.5 +/- 2.4%) and low-flux dialysis (+1.7 +/- 3.2%). The homocysteine reduction ratio was not different for the three membranes: 0.39 +/- 0.03 for the super-flux, 0.47 +/- 0.02 for the high-flux and 0.39 +/- 0.02 for the low-flux dialyser. The amount of Hcy recovered in the dialysate during a single dialysis session was also similar: 117.5 +/- 3.6 micro mol during super-flux, 95.3 +/- 11.5 micro mol during high-flux and 116.5 +/- 11.6 micro mol during low-flux dialysis. CONCLUSION: Super-flux dialysis significantly lowers tHcy in chronic haemodialysis patients. Improved removal of middle-molecule uraemic toxins with inhibitory effects on Hcy-metabolizing enzymes, rather than better dialytic clearance of Hcy itself, may explain the beneficial effect of the super-flux membrane.


Subject(s)
Homocysteine/blood , Kidney Failure, Chronic/therapy , Membranes, Artificial , Renal Dialysis/methods , Adult , Aged , Aged, 80 and over , Female , Humans , Kidney Failure, Chronic/blood , Male , Middle Aged
2.
Am J Kidney Dis ; 41(4): 877-83, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12666075

ABSTRACT

The authors report on a premenopausal female hemodialysis patient with relapsing pneumothorax, in whom the diagnosis of pulmonary lymphangioleiomyomatosis (LAM) was made. Ten years earlier, she had retroperitoneal bleeding from a kidney tumor corresponding to an angiomyolipoma (AML). The association between renal AML and pulmonary LAM is reviewed. Renal AML represents the most frequent extrapulmonary manifestation of pulmonary LAM. It is found in 32% to 60 % of cases in which a systematic search with abdominal computed tomography (CT) scan is done. The latter approach is advised to help avoid complications caused by renal AML. Therapeutic recommendations for renal AML are based on tumor size or presence of symptoms. Conversely, premenopausal women presenting with AML should be investigated for associated pulmonary LAM with high-resolution CT scan. Because LAM is very likely estrogen dependent, one of the several proposed antiestrogen therapies should be considered. Finally, there is significant overlap between renal AML, pulmonary LAM, and tuberous sclerosis. The latter should therefore be actively searched for in case of either AML or LAM.


Subject(s)
Angiomyolipoma/pathology , Kidney Neoplasms/pathology , Lung Neoplasms/pathology , Lymphangioleiomyomatosis/pathology , Neoplasms, Multiple Primary , Neoplasms, Second Primary , Postoperative Complications/pathology , Adult , Angiomyolipoma/surgery , Antineoplastic Agents, Hormonal/therapeutic use , Estrogen Receptor Modulators/therapeutic use , Female , Glomerulonephritis, Membranoproliferative/complications , Humans , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/surgery , Kidney Neoplasms/surgery , Kidney Transplantation , Lung Neoplasms/drug therapy , Lymphangioleiomyomatosis/drug therapy , Nephrectomy , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...